Appointment
Dietmar Berger returns to big pharma
Dietmar Berger has almost 20 years of experience in the field of oncology, and only a scant year ago left big pharma to work for allogeneic T-cell immunotherapy company Atara Biotherapeutics as Global Head of Research and Development. Atara earlier this week confirmed that Novartis Oncology's Global Head Cell & Gene, Pascale Touchon, was joining the company as CEO, and also confirmed that Dr. Berger had resigned from the company effective as of May 31, 2019.